Level Biotechnology Inc.

Total Valuation

Level Biotechnology Inc. carries a market capitalization of 1.04B, placing it among publicly traded companies globally. Its enterprise value stands at 868.17M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Level Biotechnology Inc. currently has 32.45M shares outstanding.

Valuation Ratios

Level Biotechnology Inc. trades at a trailing price-to-earnings ratio of 13.43. The price-to-sales ratio is 1.45, and the price-to-book ratio stands at 2.65.

Enterprise Valuation

On an enterprise value basis, Level Biotechnology Inc. trades at an EV/EBITDA multiple of 10.40 and an EV/FCF ratio of 9.39. The EV/Sales ratio of 1.18 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 10.40 provides insight into valuation relative to core operating earnings.

Financial Position

Level Biotechnology Inc. maintains a current ratio of 1.82, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.38, indicating moderate leverage, while an interest coverage ratio of 417.59 demonstrates strong ability to service its debt obligations.

Financial Efficiency

Level Biotechnology Inc. posts a return on equity of 20.03 and a return on invested capital of 11.57.

Taxes

Over the trailing twelve months, Level Biotechnology Inc. has paid 17.88M in income taxes, reflecting an effective tax rate of 18.32.

Stock Price Statistics

Level Biotechnology Inc.'s stock has declined approximately -0.46656299% over the past 52 weeks. The 50-day moving average sits at 32.89, while the 200-day moving average is 33.22.

Income Statement

Over the trailing twelve months, Level Biotechnology Inc. generated 736.59M in revenue and converted that into 79.70M in net income, yielding earnings per share of 2.44. EBITDA reached 83.52M, while operating income came in at 83.52M.

Balance Sheet

Level Biotechnology Inc. holds 210.34M in cash and equivalents against 7.98M in total debt, resulting in a net debt position of -210.34M. Total book value stands at 404.71M, with working capital of 225.26M providing operational flexibility.

Cash Flow

Level Biotechnology Inc. produced 59.61M in operating cash flow over the past twelve months. After subtracting -32.67M in capital expenditures, free cash flow totaled 26.94M - equivalent to 0.83 per share.

Margins

Level Biotechnology Inc. operates with a gross margin of 34.99, reflecting its pricing power and cost economics. The operating margin of 11.34 and net profit margin of 10.82 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Level Biotechnology Inc.'s most recent stock split took place on August 5, 2011 with a 20:21 split ratio.

Scores

Level Biotechnology Inc. posts an Altman Z-Score of 3.85, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.